LeMaitre Vascular, Inc. $LMAT Shares Bought by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 15.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 67,492 shares of the medical instruments supplier’s stock after purchasing an additional 8,871 shares during the quarter. Aptus Capital Advisors LLC owned 0.30% of LeMaitre Vascular worth $5,906,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its position in LeMaitre Vascular by 0.4% in the third quarter. Dimensional Fund Advisors LP now owns 462,679 shares of the medical instruments supplier’s stock worth $40,486,000 after acquiring an additional 1,677 shares in the last quarter. Segall Bryant & Hamill LLC boosted its position in shares of LeMaitre Vascular by 2.9% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 85,159 shares of the medical instruments supplier’s stock worth $7,452,000 after purchasing an additional 2,364 shares in the last quarter. Bahl & Gaynor Inc. grew its stake in shares of LeMaitre Vascular by 1.7% during the 3rd quarter. Bahl & Gaynor Inc. now owns 124,981 shares of the medical instruments supplier’s stock worth $10,937,000 after purchasing an additional 2,066 shares during the period. Caitlin John LLC increased its holdings in shares of LeMaitre Vascular by 2.3% in the 3rd quarter. Caitlin John LLC now owns 15,984 shares of the medical instruments supplier’s stock valued at $1,399,000 after purchasing an additional 366 shares in the last quarter. Finally, R Squared Ltd purchased a new position in shares of LeMaitre Vascular in the 3rd quarter valued at about $274,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $107.39 on Friday. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $115.33. The stock has a market cap of $2.45 billion, a P/E ratio of 42.78, a PEG ratio of 3.09 and a beta of 0.66. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average of $89.29 and a two-hundred day moving average of $88.77.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The business had revenue of $64.45 million for the quarter, compared to analyst estimates of $62.98 million. During the same period in the prior year, the business earned $0.49 earnings per share. The company’s quarterly revenue was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th will be issued a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date is Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s payout ratio is currently 31.87%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LMAT shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Monday, November 10th. Citizens Jmp upped their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, February 24th. Finally, Wells Fargo & Company boosted their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $105.80.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the sale, the insider directly owned 6,677 shares in the company, valued at $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Roberts sold 8,464 shares of the stock in a transaction on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the sale, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. The trade was a 32.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 215,438 shares of company stock valued at $23,062,911. Corporate insiders own 9.50% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.